Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

PTGX Protagonist Therapeutics Inc

Price (delayed)

$45.66

Market cap

$2.83B

P/E Ratio

50.73

Dividend/share

N/A

EPS

$0.9

Enterprise value

$2.7B

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 ...

Highlights
The quick ratio has grown by 33% from the previous quarter and by 4.9% YoY
The equity has grown by 23% YoY and by 2% from the previous quarter
PTGX's P/E is 125% above its last 4 quarters average of 22.5
The net income has dropped by 80% since the previous quarter and by 65% year-on-year

Key stats

What are the main financial stats of PTGX
Market
Shares outstanding
61.98M
Market cap
$2.83B
Enterprise value
$2.7B
Valuations
Price to earnings (P/E)
50.73
Price to book (P/B)
4.07
Price to sales (P/S)
13.84
EV/EBIT
47.33
EV/EBITDA
45.05
EV/Sales
13
Earnings
Revenue
$207.8M
Gross profit
$207.8M
Operating income
$27.22M
Net income
$56.19M
EBIT
$57.09M
EBITDA
$59.97M
Free cash flow
$335.29M
Per share
EPS
$0.9
EPS diluted
$0.78
Free cash flow per share
$5.33
Book value per share
$11.23
Revenue per share
$3.3
TBVPS
$11.79
Balance sheet
Total assets
$742.13M
Total liabilities
$53.08M
Debt
$11.36M
Equity
$689.05M
Working capital
$570.75M
Liquidity
Debt to equity
0.02
Current ratio
17.26
Quick ratio
16.36
Net debt/EBITDA
-2.14
Margins
EBITDA margin
28.9%
Gross margin
100%
Net margin
27%
Operating margin
13.1%
Efficiency
Return on assets
8.3%
Return on equity
9.2%
Return on invested capital
12.3%
Return on capital employed
8.1%
Return on sales
27.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTGX stock price

How has the Protagonist Therapeutics stock price performed over time
Intraday
-0.54%
1 week
2.63%
1 month
-1.08%
1 year
49.51%
YTD
18.29%
QTD
-5.58%

Financial performance

How have Protagonist Therapeutics's revenue and profit performed over time
Revenue
$207.8M
Gross profit
$207.8M
Operating income
$27.22M
Net income
$56.19M
Gross margin
100%
Net margin
27%
PTGX financials
PTGX's operating income has dropped by 89% since the previous quarter and by 82% year-on-year
The net income has dropped by 80% since the previous quarter and by 65% year-on-year
The operating margin has plunged by 77% from the previous quarter and by 72% YoY
The net margin has dropped by 57% since the previous quarter and by 48% year-on-year

Price vs fundamentals

How does PTGX's price correlate with its fundamentals
Price vs fundamentals
Earnings waterfall
Price vs fair value

Growth

What is Protagonist Therapeutics's growth rate over time
PTGX growth chart

Valuation

What is Protagonist Therapeutics stock price valuation
P/E
50.73
P/B
4.07
P/S
13.84
EV/EBIT
47.33
EV/EBITDA
45.05
EV/Sales
13
Valuation vs average
Price to earnings (P/E)
PTGX's P/E is 125% above its last 4 quarters average of 22.5
Protagonist Therapeutics's EPS has shrunk by 80% QoQ and by 66% YoY
Price to book (P/B)
The equity has grown by 23% YoY and by 2% from the previous quarter
The P/B is 10% more than the 5-year quarterly average of 3.7
Price to sales (P/S)
The stock's price to sales (P/S) is 86% less than its 5-year quarterly average of 98.5 but 57% more than its last 4 quarters average of 8.8
Protagonist Therapeutics's revenue has shrunk by 52% QoQ and by 34% YoY

Efficiency

How efficient is Protagonist Therapeutics business performance
The ROIC has plunged by 87% YoY and by 81% from the previous quarter
The company's return on equity has shrunk by 81% QoQ and by 79% YoY
PTGX's ROA has dropped by 80% since the previous quarter and by 79% year-on-year
Protagonist Therapeutics's return on sales has shrunk by 57% QoQ and by 48% YoY

Dividends

What is PTGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTGX.

Financial health

How did Protagonist Therapeutics financials performed over time
Assets vs liabilities
The current ratio is up by 38% since the previous quarter and by 10% year-on-year
The quick ratio has grown by 33% from the previous quarter and by 4.9% YoY
Debt vs equity
The debt is 98% smaller than the equity
The equity has grown by 23% YoY and by 2% from the previous quarter
The debt has grown by 4.5% since the previous quarter
Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.